Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.
Dunkel Y, Diao K, Aznar N, Swanson L, Liu L, Zhu W, Mi XY, Ghosh P.
Dunkel Y, et al. Among authors: ghosh p.
FASEB J. 2016 Nov;30(11):3702-3713. doi: 10.1096/fj.201600500. Epub 2016 Jul 20.
FASEB J. 2016.
PMID: 27440794
Free PMC article.
A Kaplan-Meier analysis of recurrence-free survival showed that the presence of tGIV, either cytoplasmic or nuclear, carried poor prognosis, but that nuclear tGIV had a greater prognostic impact (P = 0.007 in early and P = 0.0048 in late clinical stages). Activated …
A Kaplan-Meier analysis of recurrence-free survival showed that the presence of tGIV, either cytoplasmic or nuclear, carried poor prognosis, …